Company: TELO
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023970
Chunk: 58

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 2
Chunk 58
---
.7 million for the six months ended June 30, 2025 and 2024, respectively.

Highlights-Three
Months Ended June 30, 2025

●
On May 15, 2025, we announced the identification of Telomir-Ag2 as a novel drug candidate following successful preclinical validation
of its antimicrobial activity. Telomir-Ag2 is a stabilized Silver(II) complex developed using the Company’s proprietary Telomir-1
platform.

●
On May 29, 2025, we announced new preclinical data from its ongoing development of Telomir-1, an investigational oral small molecule
candidate being developed for the treatment of age-related macular degeneration.

●
On June 5, 2025, we announced new data from a preclinical study of its lead compound, Telomir-1, in a validated animal model of Werner
Syndrome (WS), an ultra-rare genetic disorder characterized by premature aging and shortened lifespan.

●
On June 11, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced new preclinical data demonstrating that its lead small molecule
candidate, Telomir-1, significantly improved neurological, behavioral, liver- and kidney-related outcomes in a clinically relevant animal
model of Wilson’s disease (ATP7B C271X -/- zebrafish).

●
On July 17, 2025, we reported new preclinical results evaluating the effects of its lead candidate, Telomir-1, in a murine xenograft
model using PC3 human prostate cancer cells. The data demonstrated that Telomir-1 reversed epigenetic silencing by DNA methylation of
the STAT1 gene, a tumor suppressor and immune response regulator, in a dose-dependent manner.

●
On July 18, 2025, we sold a total of 1,100,000 shares of its common stock, no par value, in block sales to institutional investors, at
an average price of $2.6045 per share (a premium to the prior day’s close), through its at-the-market equity offering facility.

●
On July 23, 2025, we reported new preclinical results showing that its lead compound, Telomir-1, restored mitochondrial function
without triggering oxidative stress or cell proliferation in human cells derived from a patient with Hutchinson-Gilford Progeria Syndrome
(HGPS